Partnering

Partnering
DRGT utilizes its proprietary Super-API drug development platform to carefully select and screen drugs and develop their Super-API compositions. Super-API drugs have improved clinical utility such as increased exposure, reduced or eliminated food effect, changed administration route.

The Company’s Super-API portfolio contains 30 compounds in indications such as oncology, pain and erectile dysfunction with significant market potential. 

If you have an interest in any of our programs, please contact us: partnering@drgtco.com. Our business development team would be happy to discuss collaboration and licensing opportunities.